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Short abstract 
 
The use of proton beam therapy (PBT) offers the opportunity to improve greater 
conformality of radiotherapy treatment delivery in some patients. However, it is 
associated with a high capital cost and the need to build new dedicated facilities. We 
discuss how the global radiotherapy community can respond to the challenge of 
producing high quality evidence of clinical benefit from PBT in adult patients 
 
In the UK, the National Cancer Research Institute funded Clinical and Radiotherapy 
Translational group (CTRad) has established the PBT Clinical Trial Strategy Group. An 
eight point framework is described that can assist the development and delivery of 
high quality clinical trials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proton Beam Therapy (PBT) is an important treatment modality in the modern 
radiotherapy (RT) armamentarium.  The high capital cost, the need to build new 
dedicated facilities and the limited high-level evidence of clinical benefit in adult 
malignancy creates a major challenge for the global radiotherapy community. This 
article will discuss the different approaches that can be used to generate the 
necessary evidence base. 
 
Background 
Despite the continuing rise in gross domestic product (GDP) spend on healthcare in 
developed countries, this is failing to keep up with the rapid pace of new treatments 
in clinical medicine [1]. There is a well-defined pathway for the evaluation of new 
systemic cancer treatments and in some countries mechanisms are in place to assess 
their cost effectiveness and availability. There is typically a substantial investment in 
the evaluation of such treatments from the pharmaceutical industry. 
 
In contrast, as new technological developments are introduced, evaluation is initially 
focused on safety rather than efficacy. Its development and subsequent adoption is 
commonly based on theoretical or perceived benefit and other incentives including 
potential financial benefit in some health care systems. High quality evidence for 
clinical benefit is less common and frequently based on observational studies. The 
generation of high quality evidence generally requires significant academic funding. 
In radiotherapy, it is not uncommon for the clinical trials to be performed after 
significant adoption of the new treatment approaches. 
 
In the surgical domain, the introduction of robotic surgery centres was achieved by 
major financial investment relying heavily on charitable and philanthropic sources. 
However high quality randomized clinical trials against the standard of care for this 
new approach are uncommon. However, a recent Cochrane review [2] did not find 
evidence of significant benefit for the use of robotic assisted prostate cancer 
surgery. Aggarwal et al [3] have recently reported changing patterns of radical 
prostatectomy centres. The increased use of robotic surgery has played a significant 
role, as well as minimum patient volume requirements, in contributing to closure of 
some cancer surgery units. In rectal cancer, Jayne et al [4] reported no evidence of 
clinical benefit for robotic compared with laparoscopic surgery in an international 
phase III trial of patients with rectal cancer. The new expensive technology does not 
always lead to better patient outcomes.  
 
Evaluating PBT 
 
How can the radiotherapy community respond to the challenge of delivering the 
high quality evidence that demonstrates the clinical benefit of proton beam therapy? 
We have a significant track record of generating high-level evidence through practice 
changing clinical trials using photons. Many were performed as two arm phase III 
trials. An example of the breadth and depth of these achievements in the last two 
decades are summarized in a recent review of five tumour sites (breast, prostate, 
head and neck, bladder and anorectal [5]. However, some of these trials required up 
to a decade to achieve their large sample size to assess long term outcomes 
including loco-regional control and survival. 
 
 Most of the trials in the review evaluated the delivery of 3D conformal external 
beam photon radiotherapy. However, the widespread introduction of external beam 
photon based stereotactic ablative radiotherapy (SABR) and intensity-modulated 
radiotherapy (IMRT) has taken place without randomized clinical trials. Retrospective 
single centre cohort series lack the rigour of prospective trials including quality 
assurance of contouring, planning and treatment delivery. However, for example, 
the UK performed two randomized trials of 3D conformal versus IMRT in breast and 
head and neck cancer, demonstrating reduced toxicity with IMRT [6,7]. Interestingly, 
the head and neck trial reported an increase in fatigue in the IMRT arm. A possible 
mechanism for this finding was an increased radiotherapy dose to the cerebellum 
and brainstem with the use of IMRT [8]. This unexpected but important clinically 
relevant finding was only identified through standardised prospective toxicity 
collection and the randomized comparison of IMRT with 3D conformal radiotherapy.  
 
Generating high quality evidence 
 
Anthony Zietman has described, in this issue, the precarious path of PBT 
development in the United States leading to demands from health care providers for 
high quality clinical evidence to justify the increased costs [9]. In the case of PBT, the 
significant capital cost investment and the relatively small number of facilities are 
key factors driving the demand for high quality evidence to support its use. Whilst 
there is consensus regarding the indications for PBT therapy in paediatric and skull 
base indications, there remains a significant lack of high quality clinical evidence for 
the majority of adult patients and including randomized clinical trials. This article will 
focus on this adult patient population. 
 
There is no international consensus on the best approach to generate the highest-
level evidence for PBT therapy. A model-based approach has been proposed for the 
selection of patients for PBT therapy [10]. This will be used in the Netherlands to 
select patients most likely to benefit from PBT, those who should be treated with 
conventional photons, and a minority of patients where there is uncertainty and 
where (randomized) clinical trials could be used to compare the two treatment 
modalities.  
 
The emphasis with this approach is to generate high quality prospective multi-centre 
data for the majority of patients treated with PBT. Some of the challenges associated 
with this approach include the need for high quality contemporary normal tissue 
complication probability (NTCP) models for optimized IMRT. Further variables 
include the dynamic delivery and motion effects, range uncertainties along with 
variable linear energy transfer (LET) and related variable radiobiological 
effectiveness (RBE) with protons. 
 
Other countries are conducting or planning clinical trials. In the USA, there is 
increasing support from insurers to fund PBT treatment in clinical trials although the 
full cost of PBT therapy may not be met. As well as the UK, the Netherlands and 
Denmark will due to open their first PBT centres in 2018. In the UK, Manchester will 
open in the Autumn 2018 and University College London Hospitals in 2020. As the 
international critical mass of PBT centres increases, how should we design and 
deliver high quality clinical trials? In this issue Anthony Zietman comments that the 
UK is very well placed to design and deliver the trials that other countries find 
difficult to perform [9].  
 
So how can the UK respond to this challenge? In the UK, radiotherapy clinical trials 
and radiotherapy research is co-ordinated by the National Cancer Research Institute 
funded Clinical and Radiotherapy Translational group (CTRad) [11]. Our aim is to 
maximize quantity and quality of life for patients receiving radiotherapy by 
optimising tumour control and minimising toxicity [12]. CTRad has a broad multi-
disciplinary membership with four workstreams covering the breadth of 
radiotherapy research from basic science, all phases of clinical trials to new 
technology and radiotherapy quality assurance. It brings together research active 
National Health Service professionals, University academics and patients. We hold 
clinical trial proposals meetings twice yearly to evaluate new concepts and assist in 
their development prior to and after funding. However, the PBT trial development is 
more complex and requires special attention [13]. The CTRad PBT clinical trial 
strategy group was therefore first convened in August 2017 to specifically address 
proton beam clinical trials development. Collectively, we have identified an eight 
point framework to address the challenge (Figure1):- 
 
i] Identifying the important scientific question – across the adult tumour sites there 
is a need to decide whether clinical trials will focus on the reduction of long term 
treatment-related toxicity and/or the improvement of cancer specific end points 
including loco-regional control or survival. Efficacy trials may consist of dose 
escalation and/or new agent radiotherapy combinations. CTRad led a recently 
published consensus statement regarding the development of the latter approach 
[14]. Long term follow up is essential to adequately characterize late failures and 
determine the pattern and severity of long term toxicities. Co-ordinated planning  
and the availability of pilot or earlier phase clinical data across a range of tumour 
sites is essential to estimate the anticipated event rates with both photons and PBT 
therapy for effective clinical trial design. 
 
ii] Clinical trial design and methodology – Radiotherapy is a complex intervention, 
and additional care is required in choosing trial methodologies [15,16]. In addition, 
pressures from both funders and the advances in personalized medicine is leading to 
significant changes in the approach to clinical trial design. The future of conventional 
large-scale phase III two-arm design is under threat; although they have a role in 
common tumour sites, it is clear other approaches are also needed. 
 
Mishra et al recently reviewed the PBT clinical trial landscape [17]. They identified a 
total of ninety-six adult interventional clinical trials with a median planned sample 
size of sixty-eight patients. The interventional trials consisted of Phase I (17%), phase 
II (53%) and phase III (15%). Only five active studies at the time of the review 
randomized patients between PBT and photons. Three further completed studies 
were noted.  
 
The UK has experience of using a clinical trial design that uses two experimental 
treatment arms in prostate and breast cancer trials [18,19]. This may help address 
efficacy and toxicity-related clinical trials questions using PBT including the 
uncertainties regarding the  RBE of protons. 
 
We will develop a network of NCRI accredited clinical trial units who plan to 
prioritise PBT trials as part of the core strategy to support trial development. Novel 
statistical and methodological expertise is essential [20]. Different approaches where 
only relatively small sample sizes may be feasible, as described by the International 
Rare Cancer Initiative (IRCI) Network studies, previously employed in systemic 
therapy trials [21]. The UK Advanced Radiotherapy Technologies Network (ART-NET) 
project group [22] aims to optimise SABR MRI radiotherapy and protons. It includes a 
clinical trial methodology workstream that focuses on clinical trial methodology for 
PBT trials and will provide advice to investigators on future clinical trial design. 
 
We will also review large scale UK funded clinical trials to determine whether an 
amendment to the existing clinical trial design will allow an embedded PBT trial 
question to be added. Different disease settings and the scientific questions will 
determine the design. There are efficiencies to this approach including a single step 
funder approved amendment to an open trial. Irrespective of the embedded design 
a tightly defined framework for evaluation of clinical end points is used for both 
photon and PBT treated patients. 
 
iii] Patient and public involvement and equipoise – In the UK the opening of two 
PBT NHS facilities in England will require many patients to travel and stay at the PBT 
facility for treatment and return to their referring centre for follow up. The very 
strong Patient and Public Involvement in CTRad and site specific groups will be of 
crucial importance to help patients understand the key issues. These include the 
need for a stronger evidence base, to understand PBT, dispel misunderstandings and 
help design clinical trials that are of interest and relevance to patients. The 
involvement of referring photon centres is crucial to understand and improve the 
level of clinical and centre equipoise. These are particular strengths in the UK 
radiotherapy community. 
 
iv] Disease specific trial development - CTRad will engage with the NCRI Clinical 
Study groups (CSG) that exist for each tumour site. They play a key role in identifying 
the key scientific questions and which tumour characteristics should be considered 
in framing a clinical trial question. We will encourage investigators interested in 
developing future trials to work collaboratively with both CTRad and the parent CSG. 
CTRad will host its first PBT trials workshop to encourage existing and new clinical 
study concept development in May 2018. 
 
v] Collaboration and development  
The complex nature of PBT clinical trial design and delivery requires close 
collaboration and leadership from both the PBT centre and surrounding referring 
photon cancers. A key aim of the CTRad PBT Clinical trial strategy group is to 
encourage and accelerate study development, ensure fit with the overall site-specific 
portfolio and avoid the development of competing studies by bringing the interested 
parties together. We seek to encourage the next generation of clinical trial leaders to 
work with an experienced clinical trial unit and to receive senior mentoring, 
preferably from experienced Chief Investigators of previous successful photon 
clinical trials. We are also keen to engage with other countries to identify the 
opportunities for international cooperation in PBT trials including international 
groups such as Particle Therapy Co-operative Group (PTCOG) [23].  There are 
different models of collaboration that would encourage the development of 
international recruitment to a common protocol. When this is not feasible, a 
common template for assessment of toxicity and efficacy to standardize outcome 
reporting in a parallel and complementary trials should be considered. 
 
vi] Radiotherapy Quality Assurance  - clinical trials deliver the highest multi-centre 
quality assurance in both treatment planning and delivery. The UK RTTQA group has 
demonstrated a clear track record in the delivery of IMRT trials in the UK [24]. 
Further work is required to deliver the additional quality assurance demands of PBT 
treatment delivery including proton specific margins, motion management 
dosimetry, imaging and adaptation. Dedicated and adequately resourced 
radiotherapy quality assurance is of critical importance to the delivery of high quality 
clinical trials. 
 
vii] Engagement with funding bodies – A coordinated approach is required within 
the UK and internationally to ensure funders of clinical trials appreciate the 
importance of the evaluation of PBT and the greater challenges associated with a 
limited number of geographically spread PBT facilities. The patient benefits and 
health care savings associated with the reduction in long term treatment-related 
toxicity is not fully appreciated in the curative setting of cancer treatment. We also 
need to assess the different models of funding that would incentivise international 
recruitment.  
 
viii] Translationally rich clinical trials - Personalised medicine has led to a significant 
increase in clinical trials that combine novel therapy evaluation with a strong 
translational research component or stratify patients according to their tumour 
biology. The evaluation of novel therapies in combination with radiotherapy should 
include the assessment of PBT as the treatment modality. The opportunity exists for 
translational researchers, particularly in the fields of DNA damage repair, tumour 
micro-environment and immune-oncology to work with the PBT community to 
deliver such studies. 
 
Conclusion 
 
We have an unprecedented, once-in-a-lifetime opportunity to initiate practice-
changing clinical studies, including randomized trials, to clarify the role of PBT for 
patients and society.  This requires engagement with the whole RT community, as 
well as with patients, carers and the wider public.  Trial design must also include 
clearly defined translational components.  CTRad is uniquely placed to guide this 
process in the UK and looks forward to the opportunity of working with the 
international community to achieve these goals.  However, we must move with 
some speed in order to exploit the opportunity that beckons. 
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